NAV

Miricorilant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Miricorilant
DrugBank Accession Number
DB16234
Background

Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 428.455
Monoisotopic: 428.171162478
Chemical Formula
C24H23F3N2O2
Synonyms
  • Miricorilant
External IDs
  • CORT-118335
  • CORT118335
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
311Y5GV21M
CAS number
1400902-13-7
InChI Key
GVVUZBSCYAVFTI-IYARVYRRSA-N
InChI
InChI=1S/C24H23F3N2O2/c25-24(26,27)19-8-4-5-15(13-19)14-20-21(28-23(31)29-22(20)30)18-11-9-17(10-12-18)16-6-2-1-3-7-16/h1-8,13,17-18H,9-12,14H2,(H2,28,29,30,31)/t17-,18-
IUPAC Name
6-[(1r,4r)-4-phenylcyclohexyl]-5-{[3-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
FC(F)(F)C1=CC(CC2=C(NC(=O)NC2=O)[C@H]2CC[C@@H](CC2)C2=CC=CC=C2)=CC=C1

References

General References
Not Available
ChemSpider
76826991
ChEMBL
CHEMBL4297602
ZINC
ZINC000101598460

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedOtherAlcohol Use Disorders (AUD)1
2CompletedTreatmentAntipsychotic-induced Weight Gain (AIWG)1
2RecruitingTreatmentNon-Alcoholic Steatohepatitis (NASH)1
2TerminatedTreatmentNon-Alcoholic Steatohepatitis (NASH)1
1CompletedBasic ScienceHealthy Volunteers (HV)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000332 mg/mLALOGPS
logP5.02ALOGPS
logP5.38Chemaxon
logS-6.1ALOGPS
pKa (Strongest Acidic)9.47Chemaxon
pKa (Strongest Basic)-4.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area58.2 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity112.46 m3·mol-1Chemaxon
Polarizability42.52 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0000900000-e6aa523a92f41dd2fb06
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0000900000-69a8a6ddab1466c88ee3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0001900000-f1508ee225d5a965a283
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-5115900000-c7b48a5818cc98abf12e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-0659300000-a0f7921d9bb6b06a273a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-8549100000-e1b1d4b641a4bde7ccdf
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at December 15, 2020 18:16 / Updated at February 21, 2021 18:55